Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Apr;72(4):583-9.
doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10.

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Monika M Schoels  1 , Désirée van der Heijde, Ferdinand C Breedveld, Gerd R Burmester, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Cem Gabay, Allan Gibofsky, Juan Jesus Gomez-Reino, Graeme Jones, Tore K Kvien, Miho Murakami, Norihiro Nishimoto, Josef S Smolen
Affiliations
Free PMC article
Meta-Analysis

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Monika M Schoels et al. Ann Rheum Dis. 2013 Apr.
Free PMC article

Erratum in

  • Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho]

Abstract

Background: Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

Objective: To review published evidence on safety and efficacy of IL-6i in inflammatory diseases.

Methods: We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov.

Results: Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable.

Conclusions: IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Search and selection process.AoSD, adult onset Still's disease; ACR, American College of Rheumatology conference, CLE, cutaneous lupus erythematosus;  EULAR, European League Against Rheumatism; IBD, inflammatory bowel disease; inhib., inhibitors, JIA, juvenile idiopathic arthritis; N, number; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis, SpA, spondyloarthropathy; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
Figure 2
Figure 2
ACR20/50/70 response rates. (A) Comparison of tocilizumab monotherapy versus combination of tocilizumab with DMARDs. (B) Comparison of 4 mg/kg versus 8 mg/kg 4-weekly. Risk ratios and 95% CIs are displayed. RR>1 favour combination therapy (in panel A) or the 4 mg/kg TCZ dose (in panel B). ACR, American College of Rheumatology
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cronstein BN. Interleukin-6. A key mediator of systemic and local symptoms in rheumatoid arthritis (abstract). Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S11–5 - PubMed
    1. http://www.abstracts2view.com/eular/(Online) (accessed Jan 2012).
    1. http://www.rheumatology.org/publications/acr_arhp_annual_meeting.asp (Online) (accessed Jan 2012).
    1. http://www.clinicaltrials.gov (Online) (accessed Jan 2012).
    1. Wallace BC, Schmid CH, Lau J, et al. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80ff. - PMC - PubMed

MeSH terms